BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 209 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,928 | -0.2% | 2,390,948 | -0.8% | 0.05% | -1.9% |
| Q2 2023 | $16,968 | -29.5% | 2,410,190 | -16.5% | 0.05% | -36.1% |
| Q1 2023 | $24,084 | -26.7% | 2,887,739 | +0.9% | 0.08% | -29.7% |
| Q4 2022 | $32,860 | -99.9% | 2,862,387 | +25.5% | 0.12% | +4.4% |
| Q3 2022 | $28,740,000 | +29.4% | 2,280,953 | +8.7% | 0.11% | +32.9% |
| Q2 2022 | $22,211,000 | -18.0% | 2,099,327 | +26.1% | 0.08% | -9.6% |
| Q1 2022 | $27,077,000 | +3.4% | 1,665,256 | -11.9% | 0.09% | +6.8% |
| Q4 2021 | $26,193,000 | +13062.3% | 1,891,160 | +11482.3% | 0.09% | +4300.0% |
| Q4 2014 | $199,000 | – | 16,328 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |